Literature DB >> 24688779

Accelerated dose escalation with proton beam therapy for non-small cell lung cancer.

Daniel R Gomez1, Joe Y Chang1.   

Abstract

Local tumor control remains challenging in many cases of non-small cell lung cancer (NSCLC), particularly those that involve large or centrally located tumors. Concurrent chemotherapy and radiation can maximize tumor control and survival for patients with locally advanced disease, but a substantial proportion of such patients cannot tolerate this therapy, and sequential chemoradiation regimens or radiation given alone at conventionally fractionated doses produces suboptimal results. An alternative approach is the use of hypofractionated proton beam therapy (PBT). The energy distribution of protons can be exploited to reduce involuntary irradiation of normal tissues, particularly the low-dose irradiation problematic in intensity-modulated (photon) radiation therapy (IMRT). Here we summarize current evidence on the use of hypofractionated PBT for both early-stage and locally advanced NSCLC, and the possibility of using hypofractionated regimens for patients who are not candidates for concurrent chemotherapy.

Entities:  

Keywords:  Hypofractionation; clinical studies; dosimetric comparisons; early-stage disease; intensity-modulated proton therapy (IMPT); locally advanced disease; passive scattering; proton beam therapy (PBT); stereotactic ablative body radiation (SABR)

Year:  2014        PMID: 24688779      PMCID: PMC3968555          DOI: 10.3978/j.issn.2072-1439.2013.11.07

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  25 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer.

Authors:  Joe Y Chang; Xiaodong Zhang; Xiaochun Wang; Yixiu Kang; Beverly Riley; Stephen Bilton; Radhe Mohan; Ritsuko Komaki; James D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-05-06       Impact factor: 7.038

3.  A phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer.

Authors:  Zheng-Fei Zhu; Min Fan; Kai-Liang Wu; Kuai-Le Zhao; Huan-Jun Yang; Gui-Yuan Chen; Guo-Liang Jiang; Li-Juan Wang; Sen Zhao; Xiao-Long Fu
Journal:  Radiother Oncol       Date:  2011-02-21       Impact factor: 6.280

4.  Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer.

Authors:  Steven P Register; Xiaodong Zhang; Radhe Mohan; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-07       Impact factor: 7.038

5.  Proton SBRT for medically inoperable stage I NSCLC.

Authors:  Kenneth D Westover; Joao Seco; Judith A Adams; Michael Lanuti; Noah C Choi; Martijn Engelsman; Henning Willers
Journal:  J Thorac Oncol       Date:  2012-06       Impact factor: 15.609

6.  Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer.

Authors:  Joe Y Chang; Ritsuko Komaki; Hong Y Wen; Beth De Gracia; Jaques B Bluett; Mary F McAleer; Stephen G Swisher; Michael Gillin; Radhe Mohan; James D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-01-20       Impact factor: 7.038

7.  Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.

Authors:  David R Spigel; John D Hainsworth; Denise A Yardley; Eric Raefsky; Jeffrey Patton; Nancy Peacock; Cindy Farley; Howard A Burris; F Anthony Greco
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

8.  Proton beam therapy for patients with medically inoperable stage I non-small-cell lung cancer at the university of tsukuba.

Authors:  Hidetsugu Nakayama; Shinji Sugahara; Mari Tokita; Hiroaki Satoh; Koji Tsuboi; Shigemi Ishikawa; Koichi Tokuuye
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-07       Impact factor: 7.038

9.  Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer.

Authors:  Daniel R Gomez; Michael Gillin; Zhongxing Liao; Caimiao Wei; Steven H Lin; Cameron Swanick; Tina Alvarado; Ritsuko Komaki; James D Cox; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-05-18       Impact factor: 7.038

10.  High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center.

Authors:  David A Bush; Gregory Cheek; Salman Zaheer; Jason Wallen; Hamid Mirshahidi; Ari Katerelos; Roger Grove; Jerry D Slater
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-08-01       Impact factor: 7.038

View more
  3 in total

1.  Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy.

Authors:  Xin Shelley Wang; Qiuling Shi; Loretta A Williams; Ritsuko Komaki; Daniel R Gomez; Steven H Lin; Joe Y Chang; Michael S O'Reilly; Raza H Bokhari; James D Cox; Radhe Mohan; Charles S Cleeland; Zhongxing Liao
Journal:  J Pain Symptom Manage       Date:  2016-02-16       Impact factor: 3.612

Review 2.  New frontiers in proton therapy: applications in cancers.

Authors:  Tai-Ze Yuan; Ze-Jiang Zhan; Chao-Nan Qian
Journal:  Cancer Commun (Lond)       Date:  2019-10-22

3.  Proton therapy needs further technological development to fulfill the promise of becoming a superior treatment modality (compared to photon therapy).

Authors:  Daniel E Hyer; Xuanfeng Ding; Yi Rong
Journal:  J Appl Clin Med Phys       Date:  2021-11-03       Impact factor: 2.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.